{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T04:42:54Z","timestamp":1766983374027,"version":"3.48.0"},"reference-count":49,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T00:00:00Z","timestamp":1766016000000},"content-version":"unspecified","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2025,12,2]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Approximately 50% of patients with Crohn\u2019s disease (CD) undergo surgery, and a significant proportion suffer from a post-surgical recurrence. We conducted a network meta-analysis to compare the efficacy of various interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Systematic review and network meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>MEDLINE, EMBASE and Cochrane Library were searched from inception up to February 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>Randomised controlled trials (RCTs), reported in any language, comparing treatments used for maintaining surgically induced remission in CD were included. The primary outcomes were clinical relapse, endoscopic relapse and withdrawal due to adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Two reviewers independently extracted data and assessed risk of bias. Certainty of evidence was rated with GRADE (Grading of Recommendations Assessment, Development and Evaluation), and SUCRA (surface under the cumulative ranking curve) was used to rank treatments.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There were 34 RCTs (n=3197). For clinical relapse, adalimumab reduced the risk of relapse compared with placebo (moderate certainty), risk ratio (RR) 0.31 (95% CI 0.16 to 0.60), moderate effect size. Two treatments may reduce the risk of clinical relapse (low certainty): 5-aminosalicylic acid (RR 0.79, 95% CI 0.66 to 0.94; trivial effect size) and purine analogues (RR 0.79, 95% CI 0.66 to 0.96; trivial effect size). All other treatments were of very low certainty. For endoscopic relapse, vedolizumab probably reduced the risk of relapse (moderate certainty), RR 0.37 (95% CI 0.17 to 0.80), large effect size. Adalimumab may reduce the risk of endoscopic relapse (low certainty), RR 0.47 (95% CI 0.27 to 0.80), large effect size. All other treatments were of very low certainty.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adalimumab and vedolizumab reduce endoscopic relapse with moderate to large effects supported by moderate to low certainty evidence. Adalimumab also prevents clinical relapse with moderate certainty. Other therapies either had evidence of trivial effect size or very low certainty evidence. Postoperative maintenance should be individualised based on patient risk and treatment profile.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjgast-2025-002086","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T12:50:16Z","timestamp":1766321416000},"page":"e002086","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Interventions for maintenance of surgically induced remission in Crohn\u2019s disease: a systematic review and network meta-analysis"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1216-5158","authenticated-orcid":false,"given":"Morris","family":"Gordon","sequence":"first","affiliation":[{"name":"University of Central Lancashire, Preston, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5245-1810","authenticated-orcid":false,"given":"Shiyao","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Medicine and Dentistry, University of Central Lancashire, Preston, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vassiliki","family":"Sinopoulou","sequence":"additional","affiliation":[{"name":"University of Central Lancashire, Preston, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Arruda Navarro","family":"Albuquerque","sequence":"additional","affiliation":[{"name":"University of Central Lancashire, Preston, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon","family":"Moran","sequence":"additional","affiliation":[{"name":"University of Nottingham, Nottingham, England, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"key":"2025122104500878000_12.1.e002086.1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318936"},{"key":"2025122104500878000_12.1.e002086.2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2012.05002.x"},{"key":"2025122104500878000_12.1.e002086.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2015.34"},{"key":"2025122104500878000_12.1.e002086.4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/s41586-025-08940-0","article-title":"Global evolution of inflammatory bowel disease across epidemiologic stages","volume":"642","author":"Hracs","year":"2025","journal-title":"Nature New Biol"},{"key":"2025122104500878000_12.1.e002086.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.10.039"},{"key":"2025122104500878000_12.1.e002086.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.12.022"},{"key":"2025122104500878000_12.1.e002086.7","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2025122104500878000_12.1.e002086.8","doi-asserted-by":"publisher","DOI":"10.1093\/ECCO-JCC\/JJAB178"},{"key":"2025122104500878000_12.1.e002086.9","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjw144"},{"key":"2025122104500878000_12.1.e002086.10","unstructured":"Liu S , Gordon M , Sinopoulou V , et al . Interventions for maintenance of surgically induced remission in Crohn\u2019s disease: protocol for a network meta-analysis. CLoK 2025. Available: https:\/\/clok.uclan.ac.uk\/54477"},{"key":"2025122104500878000_12.1.e002086.11","doi-asserted-by":"crossref","first-page":"S","DOI":"10.1016\/S0016-5085(24)01957-7","article-title":"Su1102 Developing explicit thresholds for outcomes to inform (grade) evidence to decision frameworks for ibd guidelines","volume":"166","author":"Sinopoulou","year":"2024","journal-title":"Gastroenterology"},{"key":"2025122104500878000_12.1.e002086.12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2022-001067","article-title":"BSG 2024 IBD guidelines protocol (standard operating procedures)","volume":"10","author":"Darie","year":"2023","journal-title":"BMJ Open Gastroenterol"},{"key":"2025122104500878000_12.1.e002086.13","doi-asserted-by":"publisher","DOI":"10.7326\/M18-3542"},{"key":"2025122104500878000_12.1.e002086.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2025122104500878000_12.1.e002086.15","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1044"},{"key":"2025122104500878000_12.1.e002086.16","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.g5630","article-title":"A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis","volume":"349","author":"Puhan","year":"2014","journal-title":"BMJ"},{"key":"2025122104500878000_12.1.e002086.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2017.10.005"},{"key":"2025122104500878000_12.1.e002086.18","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2023-102559"},{"key":"2025122104500878000_12.1.e002086.19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.gastro.2016.10.039","article-title":"American Gastroenterological Association Institute Technical Review on the Management of Crohn\u2019s Disease After Surgical Resection","volume":"152","author":"Regueiro","year":"2017","journal-title":"Gastroenterology"},{"key":"2025122104500878000_12.1.e002086.20","doi-asserted-by":"crossref","DOI":"10.1093\/ecco-jcc\/jjad212.0886","article-title":"P756 Efficacy and safety of medical therapies for maintenance of surgically induced remission in Crohn\u2019s disease: A systematic review and network meta-analysis","volume":"18","author":"Sinopoulou","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2025122104500878000_12.1.e002086.21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13847","article-title":"Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn\u2019s disease and ulcerative colitis","volume":"45","author":"Mao","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2025122104500878000_12.1.e002086.22","article-title":"Interventions for maintenance of surgically induced remission in Crohn\u2019s disease: a network meta-analysis","volume":"9","author":"Iheozor-Ejiofor","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025122104500878000_12.1.e002086.23","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2024-334395"},{"key":"2025122104500878000_12.1.e002086.24","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1093\/ecco-jcc\/jjae089","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Surgical Treatment","volume":"18","author":"Adamina","year":"2024","journal-title":"Journal of Crohn\u2019s and Colitis"},{"key":"2025122104500878000_12.1.e002086.25","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1053\/j.gastro.2016.10.038","article-title":"American Gastroenterological Association Institute Guideline on the Management of Crohn\u2019s Disease After Surgical Resection","volume":"152","author":"Nguyen","year":"2017","journal-title":"Gastroenterology"},{"key":"2025122104500878000_12.1.e002086.26","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S2468-1253(24)00044-X","article-title":"Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn\u2019s disease: 3-year data from the prospective, multicentre PANTS cohort study","volume":"9","author":"Chanchlani","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025122104500878000_12.1.e002086.27","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025122104500878000_12.1.e002086.28","unstructured":"National Institute of Health and Care Excellence . Crohn\u2019s disease: management [NG129]. 2019. Available: www.nice.org.uk\/guidance\/ng129\/evidence\/postsurgical-maintenance-of-remission-pdf-6777581006"},{"key":"2025122104500878000_12.1.e002086.29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease","volume":"14","author":"Torres","year":"2020","journal-title":"Medical Treatment J Crohns Colitis"},{"key":"2025122104500878000_12.1.e002086.30","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/2050640620945949","article-title":"The use of 5-aminosalicylate for patients with Crohn\u2019s disease in a prospective European inception cohort with 5 years follow-up - an Epi-IBD study","volume":"8","author":"Burisch","year":"2020","journal-title":"United European Gastroenterol J"},{"key":"2025122104500878000_12.1.e002086.31","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4292\/wjgpt.v8.i2.99","article-title":"5-Aminosalicylates to maintain remission in Crohn\u2019s disease: Interpreting conflicting systematic review evidence","volume":"8","author":"Gordon","year":"2017","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"2025122104500878000_12.1.e002086.32","article-title":"Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn\u2019s disease","volume":"8","author":"Gjuladin-Hellon","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025122104500878000_12.1.e002086.33","first-page":"11356","article-title":"Azathioprine for prevention of clinical recurrence in Crohn\u2019s disease patients with severe endoscopic recurrence: an IG-IBD randomized double-blind trial","volume":"24","author":"Orlando","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2025122104500878000_12.1.e002086.34","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.01.010"},{"key":"2025122104500878000_12.1.e002086.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2013.04.020"},{"key":"2025122104500878000_12.1.e002086.36","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.07.010"},{"key":"2025122104500878000_12.1.e002086.37","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.072"},{"key":"2025122104500878000_12.1.e002086.38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S2468-1253(24)00317-0","article-title":"Vedolizumab to prevent postoperative recurrence of Crohn\u2019s disease (REPREVIO): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"10","author":"D\u2019Haens","year":"2025","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025122104500878000_12.1.e002086.39","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1093\/ecco-jcc\/jjae015","article-title":"Azathioprine Plus Exclusive Enteral Nutrition Versus Azathioprine Monotherapy for the Prevention of Postoperative Recurrence in Patients with Crohn\u2019s Disease: An Open-Label, Single-Centre, Randomized Controlled Trial","volume":"18","author":"Duan","year":"2024","journal-title":"J Crohns Colitis"},{"key":"2025122104500878000_12.1.e002086.40","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-2036.1994.tb00158.x","article-title":"Oral mesalazine (5\u2010aminosalicylic acid; Asacol) for the prevention of post\u2010operative recurrence of Crohn\u2019s disease","volume":"8","author":"Caprilli","year":"1994","journal-title":"Aliment Pharmacol Ther"},{"key":"2025122104500878000_12.1.e002086.41","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.cgh.2020.05.037","article-title":"High-Dose Vitamin D Does Not Prevent Postoperative Recurrence of Crohn\u2019s Disease in a Randomized Placebo-Controlled Trial","volume":"19","author":"de Bruyn","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2025122104500878000_12.1.e002086.42","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s00595-018-1627-x","article-title":"Postoperative therapy with infliximab for Crohn\u2019s disease: a 2-year prospective randomized multicenter study in Japan","volume":"48","author":"Fukushima","year":"2018","journal-title":"Surg Today"},{"key":"2025122104500878000_12.1.e002086.43","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1093\/ecco-jcc\/jjx051","article-title":"Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn\u2019s Disease Recurrence. A GETECCU Randomised Trial","volume":"11","author":"L\u00f3pez-Sanrom\u00e1n","year":"2017","journal-title":"J Crohns Colitis"},{"key":"2025122104500878000_12.1.e002086.44","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.10.051"},{"key":"2025122104500878000_12.1.e002086.45","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.287"},{"key":"2025122104500878000_12.1.e002086.46","doi-asserted-by":"crossref","first-page":"306","DOI":"10.14309\/ajg.0000000000002509","article-title":"Prognostic Value of the Modified Rutgeerts Score for Long-Term Outcomes After Primary Ileocecal Resection in Crohn\u2019s Disease","volume":"119","author":"Bak","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2025122104500878000_12.1.e002086.47","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-325575"},{"key":"2025122104500878000_12.1.e002086.48","doi-asserted-by":"crossref","first-page":"7795","DOI":"10.3748\/wjg.v21.i25.7795","article-title":"Clinical predictors of thiopurine-related adverse events in Crohn\u2019s disease","volume":"21","author":"Moran","year":"2015","journal-title":"World J Gastroenterol"},{"key":"2025122104500878000_12.1.e002086.49","doi-asserted-by":"crossref","unstructured":"Sinopoulou V , Gordon M , Liu S , et al . Immunomodulators and Advanced Therapies for Induction of Remission in Crohn\u2019s Disease: A Systematic Review and Network Meta-Analysis. Inflamm Bowel Dis 2025.:izaf191. doi:10.1093\/ibd\/izaf191","DOI":"10.1093\/ibd\/izaf191"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2025-002086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T12:50:20Z","timestamp":1766321420000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2025-002086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,21]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjgast-2025-002086"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2025-002086","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}